Want to see OTLC full AI Analyst Report?
OTLC Stock Chart & Stats
$0.08
>-$0.01(-12.62%)
At close: 4:00 PM EST
$0.08
>-$0.01(-12.62%)
Day’s Range― - ―
52-Week Range$0.02 - $0.11
Previous CloseN/A
Volume643.67K
Average Volume (3M)410.07K
Market Cap
$18.19M
Enterprise Value$16.73T
Total Cash (Recent Filing)$63.61B
Total Debt (Recent Filing)$16.79T
Price to Earnings (P/E)<0.1
Beta-0.06
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.58
Shares Outstanding443,615,720
10 Day Avg. Volume544,661
30 Day Avg. Volume410,075
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap919.76K
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda48.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
IP And Strategic AssetsThe Lunai merger granted Oncotelic preferred equity and a broad, perpetual license to exploit transferred IP outside constrained fields. This materially strengthens long-term R&D optionality and reduces barriers to commercializing platform assets, supporting sustainable pipeline development.
Clinical And Platform ProgressAdvancing a Phase 2/3 program and multiple Deciparticle candidates meaningfully de-risks portions of the pipeline over 2–6 months. Combined with GMP manufacturing capability and AI biomarker work, this supports scalable clinical development and longer-term commercialization prospects.
Low Reported LeverageModest reported leverage reduces immediate solvency risk and preserves flexibility to raise capital or support operations. For an early-stage biotech, a low debt burden improves runway management and limits fixed financing costs that could otherwise constrain clinical investment.
Bears Say
Negative Cash FlowConsistent negative operating and free cash flow shows the business cannot self-fund development activities and will rely on external financing. Persistent cash burn increases dilution risk and constrains the company's ability to sustainably scale clinical programs without continued funding.
Lack Of Commercial RevenueMinimal commercial revenue and persistent net losses mean the company lacks an internal revenue buffer to fund operations. This weak earnings profile lowers margin sustainability and prolongs dependence on partnership, licensing, or capital markets to support long-term development.
Dilutive, High-Cost FinancingReliance on convertible notes with steep discounts, high interest and commitment shares signals recurring dilutive and relatively expensive financing needs. Such instruments erode shareholder value and reflect structural funding vulnerability for sustaining multi-year clinical programs.
Oncotelic Therapeutics News
OTLC FAQ
What was Oncotelic Therapeutics’s price range in the past 12 months?
Oncotelic Therapeutics lowest stock price was $0.01 and its highest was $0.11 in the past 12 months.
What is Oncotelic Therapeutics’s market cap?
Oncotelic Therapeutics’s market cap is $18.19M.
When is Oncotelic Therapeutics’s upcoming earnings report date?
Oncotelic Therapeutics’s upcoming earnings report date is Aug 24, 2026 which is in 44 days.
How were Oncotelic Therapeutics’s earnings last quarter?
Currently, no data Available
Is Oncotelic Therapeutics overvalued?
According to Wall Street analysts Oncotelic Therapeutics’s price is currently Overvalued.
Does Oncotelic Therapeutics pay dividends?
Oncotelic Therapeutics does not currently pay dividends.
What is Oncotelic Therapeutics’s EPS estimate?
Oncotelic Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncotelic Therapeutics have?
Oncotelic Therapeutics has 443,615,720 shares outstanding.
What happened to Oncotelic Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oncotelic Therapeutics?
Currently, no hedge funds are holding shares in OTLC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncotelic Therapeutics
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---